Bone Marrow Transplant. 2014 Feb;49(2):195-200. doi: 10.1038/bmt.2013.147. Epub 2013 Sep 30.
Severe adverse events (SAE) and late hematological malignancies have been reported after PBSC donation. No prospective data on incidence and risk factors have been available for family donors so far. The Japan Society for Hematopoietic Cell Transplantation (JSHCT) introduced therefore in 2000 a mandatory registration system. It defined standards for donor eligibility and asked harvest centers to report any SAE immediately. All donors were examined at day 30 and were to be contacted once each year for a period of 5 years. Acute SAEs within day 30 were reported from 47/3264 donations (1.44%) with 14 events considered as unexpected and severe (0.58%). No donor died within 30 days. Late SAEs were reported from 39/1708 donors (2.3%). The incidence of acute SAEs was significantly higher among donors not matching the JSHCT standards (P=0.0023). Late hematological malignancies in PBSC donors were not different compared with a retrospective cohort of BM donors (N:1/1708 vs N:2/5921; P=0.53). In conclusion, acute and late SAEs do occur in PBSC donors at relatively low frequency but risk factors can be defined.
PBSC 捐献后有报道称出现严重不良事件(SAE)和晚期血液系统恶性肿瘤。迄今为止,尚无针对家族供体发病率和危险因素的前瞻性数据。因此,日本造血细胞移植学会(JSHCT)于 2000 年引入了强制性登记系统。它为供体资格制定了标准,并要求采集中心立即报告任何 SAE。所有供体在第 30 天接受检查,并在 5 年内每年联系一次。从 47/3264 次捐献中报告了 30 天内的急性 SAE(1.44%),其中 14 项被认为是意外和严重的(0.58%)。无捐献者在 30 天内死亡。从 39/1708 名供体中报告了晚期 SAE(2.3%)。不符合 JSHCT 标准的供体发生急性 SAE 的发生率明显更高(P=0.0023)。与 BM 供体的回顾性队列相比,PBSC 供体的晚期血液系统恶性肿瘤没有差异(N:1/1708 与 N:2/5921;P=0.53)。总之,PBSC 供体中确实会以相对较低的频率发生急性和晚期 SAE,但可以定义危险因素。